|
|
||||||||
Articles |
The recent cloning of the thyroidal protein that is responsible for iodide transport, the sodium iodide symporter (hNIS), has made possible studies designed to characterize its structure, function and expression in thyroidal tissues. Using a mannose binding protein (MBP)-hNIS fusion protein as antigen, we have developed mouse monoclonal antibodies against hNIS to utilize as tools in such studies. Twenty-four clones were initially recovered which recognized the MBP-hNIS fusion protein, but only two of them were specific for hNIS while the others recognized MBP alone. Both antibodies were found to be immunoglobulin G (IgG) 1kappa (kappa). The specificity of antibodies was tested by Western blotting using membranes prepared from COS-7 cells transiently transfected with the pcDNA3 plasmid containing the full-length hNIS cDNA, or cells transfected with the pcDNA3 vector. A major band with a molecular weight (MW) of approximately 97 kDa, and several minor bands with MW of approximately 160 kDa, approximately 68 kDa, approximately 30 kDa and approximately 15 kDa, were detected specifically in the hNIS-transfected cells. After enzymatic deglycosylation, the major band was present at 68 kDa, as expected based upon the amino acid sequence of hNIS. Immunohistochemistry was performed with several different types of thyroid tissue and non-thyroidal tissues, using the monoclonal antibodies. Strong immunostaining was observed in Graves' tissue, with intermediate staining in papillary and follicular thyroid cancers and an absence of staining in Hurthle cell cancer. The staining was specific for the follicular epithelium and was concentrated in the basolateral portion of the cell membrane. These monoclonal hNIS antibodies should prove useful in the characterization of NIS expression in benign and malignant thyroid tissue and in studies characterizing its structure and function.
This article has been cited by other articles:
![]() |
S. J. Lim, J. C. Paeng, S. J. Kim, S. Y. Kim, H. Lee, and D. H. Moon Enhanced Expression of Adenovirus-Mediated Sodium Iodide Symporter Gene in MCF-7 Breast Cancer Cells with Retinoic Acid Treatment J. Nucl. Med., March 1, 2007; 48(3): 398 - 404. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Unterholzner, M. J. Willhauck, N. Cengic, M. Schutz, B. Goke, J. C. Morris, and C. Spitzweg Dexamethasone Stimulation of Retinoic Acid-Induced Sodium Iodide Symporter Expression and Cytotoxicity of 131-I in Breast Cancer Cells J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 69 - 78. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Cengic, C. H. Baker, M. Schutz, B. Goke, J. C. Morris, and C. Spitzweg A Novel Therapeutic Strategy for Medullary Thyroid Cancer Based on Radioiodine Therapy following Tissue-Specific Sodium Iodide Symporter Gene Expression J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4457 - 4464. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A Fragoso, V. Fernandez, R. Forteza, S. H Randell, M. Salathe, and G. E Conner Transcellular thiocyanate transport by human airway epithelia J. Physiol., November 15, 2004; 561(1): 183 - 194. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Trouttet-Masson, S. Selmi-Ruby, F. Bernier-Valentin, V. Porra, N. Berger-Dutrieux, M. Decaussin, J.-L. Peix, A. Perrin, C. Bournaud, J. Orgiazzi, et al. Evidence for Transcriptional and Posttranscriptional Alterations of the Sodium/Iodide Symporter Expression in Hypofunctioning Benign and Malignant Thyroid Tumors Am. J. Pathol., July 1, 2004; 165(1): 25 - 34. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Lassmann, M. Luster, H. Hanscheid, and C. Reiners Impact of 131I Diagnostic Activities on the Biokinetics of Thyroid Remnants J. Nucl. Med., April 1, 2004; 45(4): 619 - 625. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. V. Scholz, N. Cengic, B. Goke, J. C. Morris, and C. Spitzweg Dexamethasone Enhances the Cytotoxic Effect of Radioiodine Therapy in Prostate Cancer Cells Expressing the Sodium Iodide Symporter J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1108 - 1116. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. De la Vieja, C. S. Ginter, and N. Carrasco The Q267E mutation in the sodium/iodide symporter (NIS) causes congenital iodide transport defect (ITD) by decreasing the NIS turnover number J. Cell Sci., February 15, 2004; 117(5): 677 - 687. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-C. Gerard, C. Daumerie, C. Mestdagh, S. Gohy, C. de Burbure, S. Costagliola, F. Miot, M.-C. Nollevaux, J.-F. Denef, J. Rahier, et al. Correlation between the Loss of Thyroglobulin Iodination and the Expression of Thyroid-Specific Proteins Involved in Iodine Metabolism in Thyroid Carcinomas J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4977 - 4983. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Spitzweg, I. V. Scholz, E. R. Bergert, D. J. Tindall, C. Y. F. Young, B. Goke, and J. C. Morris Retinoic Acid-Induced Stimulation of Sodium Iodide Symporter Expression and Cytotoxicity of Radioiodine in Prostate Cancer Cells Endocrinology, August 1, 2003; 144(8): 3423 - 3432. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Dohan, A. De la Vieja, V. Paroder, C. Riedel, M. Artani, M. Reed, C. S. Ginter, and N. Carrasco The Sodium/Iodide Symporter (NIS): Characterization, Regulation, and Medical Significance Endocr. Rev., February 1, 2003; 24(1): 48 - 77. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kondo, N. Nakamura, K. Suzuki, S.-i. Murata, A. Muramatsu, A. Kawaoi, and R. Katoh Expression of Human Pendrin in Diseased Thyroids J. Histochem. Cytochem., February 1, 2003; 51(2): 167 - 173. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Castro, E. R. Bergert, J. R. Goellner, I. D. Hay, and J. C. Morris Immunohistochemical Analysis of Sodium Iodide Symporter Expression in Metastatic Differentiated Thyroid Cancer: Correlation with Radioiodine Uptake J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5627 - 5632. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kogai, J. M. Hershman, K. Motomura, T. Endo, T. Onaya, and G. A. Brent Differential Regulation of the Human Sodium/Iodide Symporter Gene Promoter in Papillary Thyroid Carcinoma Cell Lines and Normal Thyroid Cells Endocrinology, August 1, 2001; 142(8): 3369 - 3379. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Spitzweg, K. J. Harrington, L. A. Pinke, R. G. Vile, and J. C. Morris The Sodium Iodide Symporter and Its Potential Role in Cancer Therapy J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3327 - 3335. [Full Text] [PDF] |
||||
![]() |
C. Spitzweg, M. K. OConnor, E. R. Bergert, D. J. Tindall, C. Y. F. Young, and J. C. Morris Treatment of Prostate Cancer by Radioiodine Therapy after Tissue-specific Expression of the Sodium Iodide Symporter Cancer Res., November 1, 2000; 60(22): 6526 - 6530. [Abstract] [Full Text] |
||||
![]() |
T. Kogai, J. J. Schultz, L. S. Johnson, M. Huang, and G. A. Brent Retinoic acid induces sodium/iodide symporter gene expression and radioiodide uptake in the MCF-7 breast cancer cell line PNAS, July 18, 2000; 97(15): 8519 - 8524. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |